Cospanon tablets 40 mg for cholelithiasis, cholecystitis, pancreatitis and urinary calculus (flopropione)

General information on Japanese Cospanon tablets 40 mg for cholelithiasis, cholecystitis, pancreatitis and urinary calculus (flopropione)

Package details: 100 tablets

Manufacturer: Eisai Co., Ltd., Japan

Active ingredients: flopropione (chemical formula C9H10O4)

Medical effect: Cospanon tablets are effective for the treatment of the following diseases and conditions:

• cholelithiasis,
• cholecystitis,
• pancreatitis,
• urinary calculus.

Contraindications and precautions: do not use for pregnant or breastfeeding women.

If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration

For adults: take 1-2 tablets (40-80 mg of the active ingredient) at a time, 3 times daily after meals. For urological disease, take 2 tablets (80 mg) at a time, 3 times daily after meals. The doctor in charge may adjust the dosage according to the disease, age or symptoms.

How effective are Cospanon tablets 40 mg from Japan for cholelithiasis, cholecystitis, pancreatitis and urinary calculus (flopropione)?

Cospanon tablets contain flopropione, a spasmolytic or antispasmodic agent. It works by relieving spasm of smooth muscle in the gastrointestinal tract and stimulating excretion of bile and pancreatic juice into the duodenum. Consequently, Cospanon tablets relieve the abdominal pain. Also, this medicine dilates the urinary duct and stimulates excretion of calculus.

Who should use Cospanon tablets 40 mg from Japan?

Cospanon tablets are effective for the treatment of cholelithiasis, cholecystitis, pancreatitis and urinary calculus. In Japan, flopropione as an antispasmodic agent is considered a part of conservative therapy, usually used together with a medicine that facilitates stone expulsion (K. Ohgaki, K. Horiuchi et al. Facilitation of expulsion of ureteral stones by addition of α1-blockers to conservative therapy // Scandinavian journal of urology and nephrology, 2010, 44(6): 420-4).